Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
LAVA Therapeutics N.V. - Ordinary Shares
(NQ:
LVTX
)
1.740
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about LAVA Therapeutics N.V. - Ordinary Shares
< Previous
1
2
3
4
Next >
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket
↗
December 14, 2022
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio.
Via
Benzinga
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
December 10, 2022
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Analyst Says This Small Cap Stock Might Be 'Game Changer' In Bispecific T Cell Engagers Space
↗
October 25, 2022
Via
Benzinga
Why LAVA Therapeutics Stock Is Up More Than 100% Today
↗
September 26, 2022
LAVA Therapeutics N.V.
Via
Benzinga
LAVA Therapeutics Skyrockets After Cancer Agreement With Seagen
↗
September 26, 2022
Via
Benzinga
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
November 16, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
November 03, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
November 03, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Cancer Program
↗
June 17, 2022
Via
Benzinga
LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
November 01, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022
↗
October 25, 2022
Upgrades
Via
Benzinga
LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
October 07, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Snap To Surge Around 20%? Here Are 5 Other Price Target Changes For Tuesday
↗
September 27, 2022
Piper Sandler raised Snap Inc. (NYSE: SNAP) price target from $11 to $12. Piper Sandler analyst Thomas Champion maintained the stock with a Neutral. Snap shares fell 1.4% to close at $10.18 on Monday.
Via
Benzinga
Nasdaq Turns Lower; Crude Oil Drops Sharply
↗
September 26, 2022
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite turning negative on Monday.
Via
Benzinga
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223
September 26, 2022
LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development
Via
Spotlight Growth
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
↗
September 27, 2022
Gainers
Via
Benzinga
Why LAVA Therapeutics Shares Are Trading Higher By 97%, Here Are 49 Stocks Moving In Monday's Mid-Day Session
↗
September 26, 2022
Gainers
Via
Benzinga
Dow Drops Over 100 Points; Crude Oil Rises Over 1%
↗
September 26, 2022
U.S. stocks traded mixed midway through trading, with the Dow Jones dropping more than 100 points on Monday.
Via
Benzinga
What Is Going on With Lava Therapeutics (LVTX) Stock Today?
↗
September 26, 2022
Lava Therapeutics (LVTX) stock is rocketing higher on Monday as investors react to an exclusive global license agreement with Seagen (SGEN).
Via
InvestorPlace
US Stocks Mostly Higher; Nasdaq Rises Over 100 Points
↗
September 26, 2022
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday.
Via
Benzinga
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
September 26, 2022
From
Seagen Inc.
Via
Business Wire
5 Value Stocks To Watch In The Healthcare Sector
↗
June 06, 2022
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
↗
September 15, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
↗
May 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
↗
July 13, 2022
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
Via
Benzinga
LAVA Therapeutics Shares Interim LAVA-051 Data From Early-Stage Cancer Trial
↗
March 07, 2022
LAVA Therapeutics NV (NASDAQ: LVTX) announced initial data from its first clinical study with LAVA-051. The presentation will include data from the first...
Via
Benzinga
52 Biggest Movers From Yesterday
↗
February 15, 2022
Gainers BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares climbed 52.8% to close at $5.56 on Monday. Collegium Pharmaceutical will acquire BioDelivery Sciences...
Via
Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
↗
February 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
40 Biggest Movers From Friday
↗
January 03, 2022
Gainers Nutriband Inc. (NASDAQ: NTRB) shares climbed 157.8% to close at $10.08 on Friday after the company announced the Korean Intellectual Property Office has fully issued its...
Via
Benzinga
The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
↗
October 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Adcom Recommends Approval Of Moderna's COVID-19 Vaccine Booster Shot For...
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
